Gufic Biosciences Limited — Board Meeting, 13-08-2025: Outcome of Board Meeting

#GuficBio just wrapped its board meeting! 🚀 Q1 FY26 consolidated results are in: Revenue from operations hit ₹223.72 Cr, with a net profit of ₹13.07 Cr. That's a solid quarter for the pharma firm, with EPS at ₹1.30. Also, the board re-appointed their Cost Auditors (Poddar & Co. for FY26) and Statutory Auditors (Mittal Agarwal & Co. for a 5-year second term, pending shareholder nod). No major strategic shifts, just business as usual on the corporate governance front. #Pharma #QuarterlyResults